Athena Diagnostics today filed its reply brief to Mayo Collaborative Services at the Supreme Court in the closely-watched petition asking the High Court to clarify U.S. patent eligibility law. The reply reiterates the points made in Athena’s petition for certiorari and dismisses Mayo’s argument in November that “any further action regarding the patentability of medical diagnostic claims such as Athena’s that employ conventional, known techniques should and does rest with Congress.” The reply comes three days after the United States Solicitor General recommended that SCOTUS grant cert in Athena or “another such case”, rather than in Hikma Pharmaceuticals v. Vanda Pharmaceuticals.
- Will SCOTUS Tell Bad Spaniels to Roll Over?
- DOJ Takes Key Step Toward Breaking Up Big Tech with Antitrust Complaint Against Google
- Federal Circuit Rejects St. Jude’s Challenge to Validity of Snyders’ Heart Valve Patent
- CAFC Affirms District Court Dismissal of Declaratory Judgment Under Doctrine of ‘Abstention’
- Federal Circuit Affirms PTAB Finding that Immunex Antibody Patent is Obvious
- American Innovators Express Support for Recent and Proposed Changes in Patent System
- This Week in Washington IP: Senate Commerce Committee to Grill Tech CEOs on Section 230, House Big Tech Antitrust Report and USPTO’s Quarterly TPAC Meeting
- Determining the Likelihood that an AI Patent Application Will Be Allowed at the USPTO
- Examining Samsung’s and LG’s LCD Patent Portfolios Following Decisions to Halt LCD Production
- Types of Subsequent Patent Applications in the United States (Part II)